IND Swift Laboratories Ltd

Shekhawati Industries Ltd, Kolte Patil Developers Ltd, Bhartiya International Ltd and Godavari Biorefineries Ltd are among the other gainers in the BSE's 'B' group today, 11 August 2026.Ind-Swift Laboratories Ltd spiked 19.99% to Rs 284.5 at 12:03 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 3.18 lakh shares were traded on the counter so far as against the average daily volumes of 27509 shares in the past one month. Shekhawati Industries Ltd soared 19.94% to Rs 16.24. The stock was the second biggest gainer in 'B' group. On the BSE, 23433 shares were traded on the counter so far as against the average daily volumes of 8536 shares in the past one month. Kolte Patil Developers Ltd surged 17.53% to Rs 545.2. The stock was the third biggest gainer in 'B' group. On the BSE, 4.39 lakh shares were traded on the counter so far as against the average daily volumes of 11601 shares in the past one month. Bhartiya International Ltd rose 17.13% to Rs 965. The stock was the fourth biggest gainer in 'B' group. On the BSE, 102 shares were traded on the counter so far as against the average daily volumes of 518 shares in the past one month. Godavari Biorefineries Ltd jumped 14.74% to Rs 275.6. The stock was the fifth biggest gainer in 'B' group. On the BSE, 2.01 lakh shares were traded on the counter so far as against the average daily volumes of 10020 shares in the past one month.

Ind-Swift Laboratories Limited informed the BSE Limited and National Stock Exchange of India that there was no deviation or variation in the use of funds raised through a preferential issue of convertible warrants, according to a statement reviewed by the company's Audit Committee for the quarter ended June 30, 2026. The company received Rs 255.61 crore out of a total issue size of Rs 314.60 crore on August 30, 2024, and noted that Rs 58.99 crore became non-receivable from Saral Incorporated VCC Sub Fund 1 due to the warrants' tenure expiring and the allottee failing to convert them into equity.

IND-SWIFT LABORATORIES LTD. announced that shareholders approved amendments to the company’s Articles of Association through an Extra-Ordinary General Meeting on August 5, 2026, via e-voting, specifically addressing the retirement of directors by rotation and re-appointment eligibility in accordance with Section 152 of the Companies Act, 2013 and applicable regulations.

Ind-Swift Laboratories Limited held its 1st Extra Ordinary General Meeting (EGM) for the financial year 2026-27 on Wednesday, August 5th, 2026, via video conferencing, according to a corporate disclosure. The meeting, chaired by Sh. Navrattan Munjal, commenced at 11:30 A.M. IST and concluded at 12:01 P.M. IST, with 52 shareholders participating, and resolutions including the issuance of up to 70,00,000 fully convertible warrants and the re-appointment of Sh. Rajinder Kumar Gupta as an independent director, approved via remote e-voting and e-voting during the EGM.

Ind-Swift Laboratories Ltd. will hold a board meeting on Monday, August 10, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, as announced to the BSE Limited and National Stock Exchange of India Limited.

Ind-Swift Laboratories Limited notified the BSE Limited and National Stock Exchange of India Limited of a corrigendum to the notice of its Extra Ordinary General Meeting scheduled for August 5, 2026, regarding a proposed preferential issue of 70,00,000 fully convertible warrants to a promoter group entity. The changes, stemming from observations by the BSE and NSE, detail the intended use of proceeds, including expansion of existing manufacturing facilities at Jawaharpur, Derabassi (PB), and Jammu (J&K), research and development, technology upgrades, and an investment in its subsidiary, ISLL Middle East LLC -FZ, Dubai, with a tentative timeline for utilization ranging from December 2028 to December 2029.

Ind-Swift Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 5 August 2026.

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 10 July 2026.

Net profit of Ind-Swift Laboratories declined 93.20% to Rs 15.11 crore in the quarter ended March 2026 as against Rs 222.27 crore during the previous quarter ended March 2025. Sales rose 22.82% to Rs 169.79 crore in the quarter ended March 2026 as against Rs 138.24 crore during the previous quarter ended March 2025. For the full year,net profit declined 83.46% to Rs 41.42 crore in the year ended March 2026 as against Rs 250.48 crore during the previous year ended March 2025. Sales rose 14.17% to Rs 641.29 crore in the year ended March 2026 as against Rs 561.71 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales169.79138.24 23 641.29561.71 14 OPM %12.11-6.66 -7.03-3.45 - PBDT25.2222.02 15 90.6659.08 53 PBT17.1114.58 17 60.0634.60 74 NP15.11222.27 -93 41.42250.48 -83 Powered by Capital Market - Live

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 28 May 2026.